JorgeDiMartinoMDPh.D.

Adjunct Clinical Assistant Professor

Dr. DiMartino is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Hematology/Oncology, 1996 - 1999
Stanford Health Care-Sponsored Stanford UniversityResidency, Pediatrics, 1993 - 1996
University of California San Diego School of MedicineClass of 1994
Cornell University Graduate School of Medical SciencesPh.D., 1988 - 1992

PubMed

112 citations
The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10
Jorge F. DiMartino, Paul M. Ayton, Everett H. Chen, Clarissa C. Naftzger, Bryan D. Young
Blood. 2002-05-15
250 citations
Microenvironment Determines Lineage Fate in a Human Model of MLL-AF9 Leukemia
Junping Wei, Mark Wunderlich, Catherine Fox, Sara Alvarez, Juan C. Cigudosa
Cancer Cell. 2008-06-10
43 citations
Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome.
Kevin Leung, Aaron N. Nguyen, Tao Shi, Lin Tang, Xiaochun Ni
Proceedings of the National Academy of Sciences of the United States of America. 2019-01-08

Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid LeukemiaAugust 22nd, 2022
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AMLAugust 17th, 2022
Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical DevelopmentFebruary 1st, 2022
Join now to see all